Collectionner le produit
Détails du produit
Synonyms
DLL4, Delta4
Source
Human DLL4 Protein, Fc Tag (DL4-H5259) is expressed from human 293 cells (HEK293). It contains AA Ser 27 - Pro 524 (Accession # NP_061947.1).
Predicted N-terminus: Ser 27
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 80.9 kDa. The protein migrates as 95-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Sterility
Negative
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 100 mM Glycine, 150 mM NaCl, 25 mM Arginine, 50 mM Tris, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human DLL4 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human DLL4 Protein, Fc Tag (Cat. No. DL4-H5259) is more than 85% and the molecular weight of this protein is around 165-210 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human DLL4 Protein, Fc Tag (Cat. No. DL4-H5259) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human DLL4 Antibody, Human IgG1 with a linear range of 1-16 ng/mL (QC tested).
Protocol
Immobilized Mouse NOTCH1, His Tag (Cat. No. NO1-M52H8) at 2 μg/mL (100 μL/well) can bind Human DLL4 Protein, Fc Tag (Cat. No. DL4-H5259) with a linear range of 0.5-8 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Human DLL4 Protein, Fc Tag (Cat. No. DL4-H5259) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Bioactivity-CELL BASE
Human DLL4 Protein, Fc Tag (Cat. No. DL4-H5259) stimulates Human Notch1 (Luc) HeLa Reporter Cell. The typical EC50 for this effect is 874 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
A***r2025-11-15
J'aimeI have been using ACRO Biosystems products since 2021, especially DLL4 Fc proteins (DL4-H5259), refer to our published article: https://pubmed.ncbi.nlm.nih.gov/37795096/, where we have used Acro-products and obtained excellent results. I am very satisfied with the consistent quality and reliability of ACRO’s products. Thanks, Ankit Tanwar Staff Scientist AECOM, NY- Z***a2022-07-06 J'aimeThis product was extremely useful for our T cell work. The vial it came in was easy to use (sometimes you'd be surprised how obtuse the packaging of a compound can be by certain companies) and has not lead to any issues with our research in many months. The only obstacle we have ever faced with adherent cells was as a result of our flat bottom plates being too old (and thus the coating wore off). So this product was more stable and consistent than the plates we put them on!
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Delta-like protein 4
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
3 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
